
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. has demonstrated a notable increase in the probability of success for its pipeline candidates, now at 25%, reflecting a strengthening of durability in their gene therapies, particularly for Hemophilia A. The company's proprietary genome editing technology, which boasts a remarkable improvement in editing efficiency of up to 50 times through optimized small AAV-packagable base editors, positions it favorably within the gene editing landscape. Furthermore, the sustained increase in FVIII expression levels in non-human primates over a period of 16 months enhances the outlook for future clinical developments, particularly with anticipated data updates and an IND filing projected for 2026.
Bears say
Metagenomi Inc. is facing a negative outlook due to potential regulatory hurdles that could hinder the approval of its pipeline candidates, which may adversely affect the company's financial projections and risk-adjusted price estimates. The company reported a net loss of $18.8 million, or $0.51 per share, in its 3Q24 financial results, indicating ongoing financial instability. Additional risks include delays in pipeline advancement, unfavorable clinical data outcomes, and safety concerns related to gene editing, which collectively pose a significant threat to Metagenomi's financial viability and market position.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares